Abstract
Background:
To study the results of interval debulking surgery (IDS) in patients treated for 'unresectable' advanced stage ovarian cancer compared with primary debulking surgery (PDS) followed by chemotherapy.
Patients and methods:
An exposed-non-exposed study including a group of 34 patients who underwent an IDS and were matched to an historic control group of 34 patients treated with PDS.
Results:
Optimal cytoreductive surgery was achieved in 94% (32 out of 34) of patients in both groups. The rates of post-operative morbidity, blood transfusion and median length of hospitalisation were significantly reduced in the study (IDS) group, but survival did not differ in both groups.
Conclusions:
IDS in patients with advanced stage ovarian cancer offers the same chance of survival as PDS, but it is better tolerated.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adenocarcinoma, Clear Cell / drug therapy
-
Adenocarcinoma, Clear Cell / pathology
-
Adenocarcinoma, Clear Cell / surgery
-
Adenocarcinoma, Mucinous / drug therapy
-
Adenocarcinoma, Mucinous / pathology
-
Adenocarcinoma, Mucinous / surgery
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Endometrioid / drug therapy
-
Carcinoma, Endometrioid / pathology
-
Carcinoma, Endometrioid / surgery
-
Case-Control Studies
-
Combined Modality Therapy
-
Cystadenocarcinoma, Serous / drug therapy
-
Cystadenocarcinoma, Serous / pathology
-
Cystadenocarcinoma, Serous / surgery
-
Female
-
Hospitalization
-
Humans
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / surgery*
-
Ovariectomy / methods*
-
Postoperative Complications
-
Survival Rate
-
Time Factors
-
Treatment Outcome